Company intelligence / Profile preview
Origenis GmbH
Planegg/Martinsried near Munich, Bavaria, Germanyorigenis.de ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Origenis has developed a robust AI-driven platform for small molecule drug discovery with a focus on neurodegenerative and neuroinflammatory diseases. Its lead programs have been spun out into Neuron23 Inc., which has raised over $113 million to advance these assets toward clinical trials. The company continues to innovate in CNS, oncology, antiviral, and ophthalmology pipelines but does not yet have late-stage or commercialized products.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Alcon (ophthalmology)Probiodrug/Vivoryon (CNS)Mestrelab Research SL (software collaboration)Kleiner Perkins & Westlake Village BioPartners et al. through partnership/spin-out with Neuron23 Inc.
Beyond the preview
Go deeper on Origenis GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Origenis GmbH.